Compare Alibaba Group (BABA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs TG Therapeutics Inc — how do they compare? Alibaba Group trades at $125.35 (market cap $308.93B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Alibaba Group is far larger — about 40.4× TG Therapeutics Inc's market cap, and Alibaba Group pays a 0.82% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BABA | TGTX | |
|---|---|---|
Market Cap | $308.93B | $7.64B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $59.06 |
52-Week Low | $94.83 | $26.94 |
Enterprise Value | $303.72B | $7.84B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $124.80, down 5.69% on the day amid ongoing legal pressures and earnings misses. The stock shows bullish technical signals with strong moving average support but faces fundamental headwinds from three consecutive quarterly EPS misses. Revenue growth remains positive at $996.35 billion for 2025, with improved net income margin of 13.05%, though cash flow turned negative at -$97.16 billion due to heavy investing activity.
Despite analyst optimism with 86% buy ratings and $195 consensus target, significant legal risks from multiple class action lawsuits and recent earnings underperformance create near-term uncertainty. The 56% upside to target suggests potential value if legal and operational challenges resolve, but investors face elevated regulatory and execution risks in the Chinese market environment.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
